- Home
- EVN vs PRTA Comparison
EVN vs PRTA Comparison
Compare EVN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | PRTA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 482.3M |
| IPO Year | 1998 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EVN | PRTA |
|---|---|---|
| Price | $10.90 | $9.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 56.5K | ★ 383.0K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.59 | $4.32 |
| 52 Week High | $11.23 | $14.60 |
Technical Indicators
Market Signals| Indicator | EVN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 60.48 |
| Support Level | $10.81 | $9.54 |
| Resistance Level | $11.17 | $10.72 |
| Average True Range (ATR) | 0.10 | 0.55 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 32.00 | 85.94 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.